For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | - | 0 | - | - |
| Research and development | - | 19,702 | 22,526 | 26,859 |
| General and administrative | - | 955 | 6,835 | 7,805 |
| Impairment of long-lived assets | - | 0 | 6,763 | - |
| Total operating expenses | - | 20,657 | 36,124 | 34,664 |
| Loss from operations | - | -20,657 | -36,124 | -34,664 |
| Interest income | - | 1,309 | 1,605 | 2,010 |
| Other income | - | 103 | 97 | 113 |
| Total other income | - | 1,412 | 1,702 | 2,123 |
| Loss before provision for income taxes | - | -19,245 | -34,422 | -32,541 |
| Personnel and related costs | 5,596 | - | - | - |
| Facility and other allocated costs | 3,468 | - | - | - |
| Research and laboratory | 7,468 | - | - | - |
| Other research and development | 573 | - | - | - |
| General and administrative | 6,579 | - | - | - |
| (benefit) provision for income taxes | - | -68 | - | - |
| Other segment (income) expense | -2,039 | - | - | - |
| Net income (loss) | -21,645 | -19,177 | -34,422 | -32,541 |
| Unrealized loss on investments | -615 | -34 | -19 | -222 |
| Comprehensive income (loss) | -22,260 | -19,211 | -34,441 | -32,763 |
| Basic EPS | -0.11 | -0.22 | -0.4 | -0.38 |
| Diluted EPS | -0.11 | -0.22 | -0.4 | -0.38 |
| Basic Average Shares | 193,474,913 | 87,502,722 | 86,464,066 | 86,238,084 |
| Diluted Average Shares | 193,474,913 | 87,425,291 | 86,464,066 | 86,238,084 |
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)